US equities
|
MU
$989.88
▼-3.80%
META
$741.86
▲+3.23%
NVDA
$226.74
▼-1.11%
SNDK
$1,489.01
▼-5.87%
SPCX
$163.34
▲+0.47%
AMD
$594.86
▼-2.18%
MSFT
$540.28
▲+0.97%
TSLA
$378.40
▼-1.12%
MU
$989.88
▼-3.80%
META
$741.86
▲+3.23%
NVDA
$226.74
▼-1.11%
SNDK
$1,489.01
▼-5.87%
SPCX
$163.34
▲+0.47%
AMD
$594.86
▼-2.18%
MSFT
$540.28
▲+0.97%
TSLA
$378.40
▼-1.12%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Eton Pharmaceuticals, Inc. - Common Stock
(NQ:
ETON
)
55.59
+0.38 (+0.69%)
Delayed Quote
Updated: 3:52 PM EDT, Oct 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Eton Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
Next >
Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules
September 28, 2026
From
Eton Pharmaceuticals
Via
GlobeNewswire
Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference
August 27, 2026
From
Eton Pharmaceuticals
Via
GlobeNewswire
Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results
August 13, 2026
From
Eton Pharmaceuticals
Via
GlobeNewswire
Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001
August 05, 2026
From
Eton Pharmaceuticals
Via
GlobeNewswire
Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
August 03, 2026
From
Eton Pharmaceuticals
Via
GlobeNewswire
Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution
July 29, 2026
From
Eton Pharmaceuticals
Via
GlobeNewswire
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)
May 19, 2026
From
Eton Pharmaceuticals
Via
GlobeNewswire
Eton Pharmaceuticals Reports First Quarter 2026 Financial Results
May 14, 2026
From
Eton Pharmaceuticals
Via
GlobeNewswire
Eton Pharmaceuticals to Participate in Upcoming Investor Conferences
May 12, 2026
From
Eton Pharmaceuticals
Via
GlobeNewswire
Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
May 04, 2026
From
Eton Pharmaceuticals
Via
GlobeNewswire
Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution
May 01, 2026
From
Eton Pharmaceuticals
Via
GlobeNewswire
Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700
April 27, 2026
-- Company’s extended-release formulation of zinc acetate will be compared to GALZIN® (zinc acetate) and a placebo for the treatment of Wilson disease --
From
Eton Pharmaceuticals
Via
GlobeNewswire
Eton Pharmaceuticals Announces CFO Succession Plan
April 16, 2026
Experienced pharmaceutical executive Judith M. Matthews to assume CFO role on June 1st
From
Eton Pharmaceuticals
Via
GlobeNewswire
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
March 19, 2026
From
Eton Pharmaceuticals
Via
GlobeNewswire
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026
March 03, 2026
From
Eton Pharmaceuticals
Via
GlobeNewswire
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution
March 02, 2026
From
Eton Pharmaceuticals
Via
GlobeNewswire
Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution
February 25, 2026
From
Eton Pharmaceuticals
Via
GlobeNewswire
Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th
February 20, 2026
From
Eton Pharmaceuticals
Via
GlobeNewswire
Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate
February 02, 2026
From
Eton Pharmaceuticals
Via
GlobeNewswire
Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results
November 06, 2025
From
Eton Pharmaceuticals
Via
GlobeNewswire
Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
October 23, 2025
From
Eton Pharmaceuticals
Via
GlobeNewswire
Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results
August 07, 2025
From
Eton Pharmaceuticals
Via
GlobeNewswire
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)
July 08, 2025
From
Eton Pharmaceuticals
Via
GlobeNewswire
Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes
June 27, 2025
From
Eton Pharmaceuticals
Via
GlobeNewswire
Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral Solution
May 28, 2025
From
Eton Pharmaceuticals
Via
GlobeNewswire
Eton Pharmaceuticals Reports First Quarter 2025 Financial Results
May 13, 2025
From
Eton Pharmaceuticals
Via
GlobeNewswire
Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025
May 01, 2025
From
Eton Pharmaceuticals
Via
GlobeNewswire
Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)
April 28, 2025
From
Eton Pharmaceuticals
Via
GlobeNewswire
Eton Pharmaceuticals Out-Licenses International Rights to Increlex®
April 01, 2025
Esteve Pharmaceuticals, S.A. will commercialize Increlex in all markets outside the U.S.
From
Eton Pharmaceuticals
Via
GlobeNewswire
Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
March 18, 2025
From
Eton Pharmaceuticals
Via
GlobeNewswire
< Previous
1
2
3
Next >
